BioSpace News Archive

According to Emergen Research, the global population health management solutions market size was USD 21.63 billion in 2019 and is expected to reach USD 48.64 billion in 2027 and register a revenue CAGR of 11.3% during the forecast period.

Major factors providing impetus to the global retinal imaging market growth include rise in global geriatric population, increasing incidences of ophthalmic disorders such as glaucoma, diabetic retinopathy, and macular degeneration, rapidly increasing patient pool, and rising awareness of early disease detection and treatment.

According to Emergen Research, the global spinal fusion devices market size was USD 7.12 billion in 2020 and is expected to reach USD 9.21 billion in 2028 and register a revenue CAGR of 3.5% during the forecast period, 2021-2028.

Transgene (Euronext Paris: TNG) (Paris:TNG), and PersonGen BioTherapeutics, today announced a strategic collaboration to evaluate the feasibility and efficacy of combination therapy associating PersonGen’s TAA06 CAR-T cell injection with intravenous (IV) administration of an armed oncolytic virus, from Transgene’s Invir.IO™ platform.

Mahana Therapeutics, a leading developer of prescription digital therapeutics designed to empower people living with chronic health conditions, today announced that Mahana has been selected for the DigitalHealth.London’s Accelerator programme.

HeartFlow Holding, Inc., the leader in revolutionizing precision heart care, announced the appointment of Timothy Barabe to its Board of Directors.

STRATA Skin Sciences, Inc. announced that it has entered into an agreement with JuvenIL, the dermatology and aesthetics portion of Trimaco, a leading distributor in Israel for medical devices and innovation, to supply STRATA’s XTRAC® excimer lasers in Israel.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced the publication of data in the journal Epilepsia from a preclinical study of PRAX-562.

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the huNOG-EXL EA (Early Access) humanized immune system (HIS) mouse.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of a case series in the journal Cardiovascular Revascularization Medicine describing successful uses of the Neovasc Reducer™ (“Reducer”) under a compassionate use protocol in the United States.